Asymmetric Nucleophilic Aromatic Substitution Enabled by Hydrogen-Bonding Catalysis
氢键催化实现不对称亲核芳香取代
基本信息
- 批准号:10746493
- 负责人:
- 金额:$ 3.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-10 至 2023-07-09
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAddressAnionsAntiviral AgentsAreaBindingBiologicalBiological TestingCOVID-19CatalysisChemical StructureChemicalsComputer ModelsCouplingDataDealkylationDevelopmentDimensionsDiseaseEbolaGoalsHealthHepatitis BHepatitis CHumanHydrochloric AcidHydrogen BondingIn SituIonsKineticsKnowledgeLibrariesLifeMedicineMethodologyMethodsModelingMolecularOrganic ChemistryOrganic SynthesisOutcomePharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhosphitesPhosphorusPollutionPreparationProceduresProductivityReactionReagentReportingResearchResolutionRouteStructureStructure-Activity RelationshipSurveysSystemTechniquesTenofovirTransition ElementsTranslatingValidationcatalystcold temperaturecombatcostdesignenantiomerimprovedinsightnovelnovel strategiesremdesivirscaffoldsmall moleculetherapeutic target
项目摘要
Project Summary/Abstract
Stereogenic-at-phosphorus (P-chiral) P(V) compounds are an increasingly important motif in the design of life-
saving pharmaceuticals such as broad spectrum anti-viral medications (Remdesivir, Sofosbuvir, Tenofovir
Alafenamide) to treat hepatitis B and C as well as Ebola and COVID-19. Despite the enormous importance of being
able to introduce P-chiral centers into compounds to develop new medications to combat existing and emergent
diseases, access to this chemical motif remains constrained by a lack of efficient chemical methods. As a result, the
diversity of structures that can be efficiently explored and produced in medicinal chemistry research is relatively
limited. Existing methods suffer from several limitations: 1) reliance on non-selective synthesis routes, which
require additional resolution steps, thus limiting the efficiency of these approaches and 2) the predominant use of
electrophilic P(V) substrates that required pre-activation steps to install an appropriately reactive leaving group.
Catalytic cross coupling approaches to access P-chiral compounds currently have relatively narrow product scopes
and often rely on expensive transition metal catalysts that must be removed assiduously before biological testing.
An attractive new approach would be an organocatalytic asymmetric phosphonium dealkylation reaction that
generates P-chiral stereogenic centers by coupling P(III) nucleophiles and electrophilic activating agents. This
approach would address the previously mentioned key limitations while enabling chemists to catalytically and
selectively control the wide range of powerful reactions know to proceed through phosphonium species.
Hydrogen-bond donor (HBD) organocatalysts are known to catalyze the formation of ionic species by anion
binding while also controlling the stereochemical outcome of nucleophilic trapping of these species. By leveraging
the powerful transition state stabilization and synergistic dual nucleophilic and electrophilic activation capabilities
unique to HBD catalysts, this approach should enable phosphonium desymmetrization to be accomplished with
exquisite enantioselectivity.
The goal of this proposal is to design an anion pair binding organocatalyst to promote the first catalytic
enantioselective phosphonium dealkylation reaction capable of producing P-chiral products. The research plan
outlines a strategy to develop such a catalyst system guided by hypothesis-driven experimentation, computational
modeling, and structure-activity studies. To add to the information gained in the reaction development, a detailed
mechanistic study of HBD organocatalyst activation of simple phosphorus (III) substrates such as phosphonites and
phosphites will be undertaken using data-intensive multi-dimensional correlation. This study will enable simple
reagents to be utilized to produce medicinally relevant enantioenriched compounds in a novel manner, contributing
enormously to medicinal research, catalyst development, and substantially contributing to scientific knowledge.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gabriel J Lovinger其他文献
Gabriel J Lovinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gabriel J Lovinger', 18)}}的其他基金
Asymmetric Nucleophilic Aromatic Substitution Enabled by Hydrogen-Bonding Catalysis
氢键催化实现不对称亲核芳香取代
- 批准号:
9907565 - 财政年份:2020
- 资助金额:
$ 3.59万 - 项目类别:
Asymmetric Nucleophilic Aromatic Substitution Enabled by Hydrogen-Bonding Catalysis
氢键催化实现不对称亲核芳香取代
- 批准号:
10311063 - 财政年份:2020
- 资助金额:
$ 3.59万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 3.59万 - 项目类别:
Research Grant